Key Points
- Insider selling: Oruka Therapeutics director Carl Dambkowski sold 12,583 shares on June 12 at an average price of $70.11, totaling about $882,194. The sale was made under a pre-arranged Rule 10b5-1 plan, and he still owned 38,743 shares afterward.
- Recent insider activity: Dambkowski also sold 22,417 shares on June 11 and 105,000 shares on May 21, bringing his recent disposal of ORKA stock to a significant level. The article notes these transactions reduced his position by 24.52% in the latest sale alone.
- Company and analyst backdrop: Oruka Therapeutics stock closed near $69.89, with a 52-week range of $10.77 to $91.00 and a market cap of $4.22 billion. Analysts remain mostly bullish overall, with a consensus rating of Moderate Buy and an average price target of $131.30.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) Director Carl Dambkowski sold 12,583 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares of the company's stock, valued at $2,716,271.73. This trade represents a 24.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Carl Dambkowski also recently made the following trade(s):
- On Thursday, June 11th, Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21.
- On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00.
Oruka Therapeutics Stock Performance
Oruka Therapeutics stock opened at $69.89 on Friday. Oruka Therapeutics, Inc. has a 52-week low of $10.77 and a 52-week high of $91.00. The firm has a 50 day moving average price of $63.40 and a two-hundred day moving average price of $43.94. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of -36.03 and a beta of -0.26.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities research analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.
Analysts Set New Price Targets
ORKA has been the subject of several analyst reports. Wall Street Zen lowered shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. UBS Group raised their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, April 28th. HC Wainwright reiterated a "buy" rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Finally, Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a "buy" rating in a research note on Monday, April 27th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.30.
Read Our Latest Stock Analysis on ORKA
Institutional Trading of Oruka Therapeutics
Several hedge funds have recently modified their holdings of ORKA. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at $28,000. BNP Paribas Financial Markets increased its stake in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after acquiring an additional 2,306 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after acquiring an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $39,000. Institutional investors own 56.44% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
